

Circulating immune cell landscape in patients who had mild ischaemic stroke

Young-Eun Cho ^{1,2}, Hyangkyu Lee,³ Heekyong R. Bae,⁴ Hyungsuk Kim,² Sijung Yun,⁵ Rany Vorn,⁶ Ann Cashion,⁷ Mary Jo Rucker,⁸ Mariam Afzal,⁹ Lawrence Latour,⁹ Jessica Gill⁶

To cite: Cho Y-E, Lee H, Bae HR, *et al.* Circulating immune cell landscape in patients who had mild ischaemic stroke. *Stroke & Vascular Neurology* 2022;**0**. doi:10.1136/svn-2021-001224

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/svn-2021-001224>).

Received 8 July 2021

Accepted 5 January 2022

ABSTRACT

Introduction Patients who had a mild ischaemic stroke who present with subtle or resolving symptoms sometimes go undiagnosed, are excluded from treatment and in some cases clinically worsen. Circulating immune cells are potential biomarkers that can assist with diagnosis in ischaemic stroke. Understanding the transcriptomic changes of each cell population caused by ischaemic stroke is critical because they work closely in a complicated relationship. In this study, we investigated peripheral blood mononuclear cells (PBMCs) transcriptomics of patients who had a stroke using a single-cell RNA sequencing to understand peripheral immune response after mild stroke based on the gene expression in an unbiased way.

Methods Transcriptomes of PBMCs from 10 patients who had an acute ischaemic stroke within 24 hours after stroke onset were compared with 9 race-matched/age-matched/gender-matched controls. Individual PBMCs were prepared with ddSeqTM (Illumina-BioRad) and sequenced on the Illumina NovaSeq 6000 platform.

Results Notable population changes were observed in patients who had a stroke, especially in NK cells and CD14⁺ monocytes. The number of NK cells was increased, which was further confirmed by flow cytometry. Functional analysis implied that the activity of NK cells also is enhanced in patients who had a stroke. CD14⁺ monocytes were clustered into two groups; dendritic cell-related CD14⁺ monocytes and NK cell-related CD14⁺ monocytes. We found CD14⁺ monocyte subclusters were dramatically reduced in patients who had a stroke.

Discussion This is the first study demonstrating the increased number of NK cells and new monocyte subclusters of mild ischaemic stroke based on the transcriptomic analysis. Our findings provide the dynamics of circulating immune response that could assist diagnosis and potential therapeutic development of mild ischaemic stroke.

INTRODUCTION

Stroke is the fifth leading cause of death in the USA and remains a serious disability for adults.^{1 2} Early and accurate detection of an ischaemic insult is paramount to initiating an appropriate acute intervention and strategies for preventing recurrence. At present, the diagnosis of stroke mostly remains based on clinical evaluation and neuroimaging assessment.³ Diagnosis is confounded by

variability in the imaging modality used and in the uncertainty in the causal relationship between specific findings and clinical presentation. Due to these risks, there is a need for biomarkers linked directly to the biology of cerebral ischaemia that can assist with diagnosis in this vulnerable population.

Peripheral immune cells are potential surrogate biomarkers in ischaemic stroke.^{4 5} Compared with images in a narrow time frame after stroke, it allows us to evaluate disease progression and predict outcomes in a more timely manner.⁶ Among circulating immune cells, monocytes have been tested as potential biomarkers. It was found that each monocyte subtype correlates with stroke severity or associated infections,⁷ and monocyte-to-high-density lipoprotein ratio and lymphocyte-to-monocyte ratio are related to patient outcome and stroke severity in patients who had an ischaemic stroke.⁸ T-cell immunoglobulin and mucin domain containing 4 (TIM-4) expression level in non-classical monocytes was significantly increased in patients who had a stroke compared with controls and correlated with National Institutes of Health Stroke Scale (NIHSS) scores.⁹ Circulating natural killer (NK) cells are another candidate of biomarkers in ischaemic stroke. A higher number of circulating NK cells and a low level of interferon gamma (IFN- γ) or perforin expression of NK cells were suggested to be used to predict a higher chance of poststroke infection.^{10 11}

However, peripheral immune response after stroke is complex because various immune cells behave in different directions and interplay with each other.¹² Sometimes, their behaviour pattern does not match surface markers that we use to differentiate cells.¹³ Therefore, in order to develop peripheral immune cell biomarkers in ischaemic stroke, we first need to have a comprehensive understanding of the dynamics of each immune cell caused by stroke incidence. In this study, we implemented single-cell RNA sequencing (scRNA-seq) to obtain an unbiased and broad



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Young-Eun Cho;
young-eun-cho@uiowa.edu

understanding of systemic immune response after stroke in peripheral blood mononuclear cells (PBMCs). We investigated the characteristics of each cell population of PBMCs from patients who had a stroke compared with controls and found significant changes in NK cells and monocytes of patients who had a stroke.

MATERIALS AND METHODS

Subjects

Patients presenting to the emergency department at Suburban Hospital in Bethesda Maryland who are within 24 hours of last known well and with clinical and imaging findings were included in this study. Once written informed consent was obtained, peripheral blood was drawn. All patients were seen by the National Institutes of Health acute stroke team and evaluated as part of their standard care. The severity of neurological symptoms was scored on NIHSS.

Flow cytometry

PBMCs were measured with an eight-colour immunophenotyping kit and a flow cytometer, MACSQuant Analyzer 10 (Miltenyi Biotec, Bergisch Gladbach, Germany). A cocktail of fluorochrome-conjugated recombinant engineered REAfinity antibodies was used for cell staining: CD3 conjugated to PE, CD4 conjugated to VioBright 667, CD8 conjugated to APC-Vio 770, CD14 conjugated to VioBlue, CD16 conjugated to VioBright 515, CD19 conjugated to PE-Vio 770, CD45 conjugated to VioGreen and CD56 conjugated to VioBright 515. Gating and analysis of flow cytometry data were performed with FlowJo (Tree-star, San Carlos, California, USA).

Single-cell RNA sequencing

Within 2 hours after blood draw, PBMCs were isolated using SepMate, Lymphoprep and EasySep Buffer (STEM-CELL Technologies, Vancouver, Canada). Detailed procedures were followed using the manufacturer's direction. Isolated PBMCs were stored at -80°C until used. Frozen PBMCs were thawed at 37°C then centrifuged at $300\times g$ for 3 min at 4°C . PBMCs were adjusted to be 3000 cells/ μL with EasySep Buffer. Illumina Bio-Rad SureCell WTA 3' Library Prep Kit (Illumina, San Diego, California, USA), along with ddSeq system (BioRad, Hercules, California, USA) were used for the library preparation process. All libraries were sequenced on NovaSeq 6000 (Illumina, San Diego, California, USA).

Single-cell RNA-seq analysis

Unique molecular identifiers were obtained from FASTQ files using SureCell RNA Single-Cell App V.1.2 in BaseSpace. Alignment was performed on University of California Santa Cruz (UCSC)'s hg38 reference genome using STAR V.2.5.2b.¹⁴ Clustering and differential gene expression analysis per cell type were performed using Seurat V.3.0.0.^{15 16} A Seurat object was constructed per subject from the filtered count table obtained from BaseSpace. Seurat objects were merged, normalized with

natural log and scaled by a default scaling factor of 10000 each for stroke subjects and for control subjects. Two thousand genes whose expressions vary from cell to cell were identified. Integration anchors were identified using the first 30 principal axes in Canonical Correlation Analysis. Rescaling was performed to make the mean value of 0 and standard deviation of 1. Principal component analysis (PCA), t-distributed stochastic neighbor embedding (t-SNE) and uniform manifold approximation and projection (UMAP) clustering were performed. Neighbouring cells were found using the first 30 principal axes from PCA, and followed by clustering assignment.

Statistics

The relative cell composition between patients who had a stroke and controls was compared with the Mann-Whitney U test with a statistical threshold as $p=0.05$ using SPSS V.27. Ingenuity pathway analysis (Qiagen, Hilden, Germany) and Enrichr were used to analyse network interactions among differentially expressed genes (DEGs) and perform the functional enrichment analysis of these DEGs.¹⁷¹⁸ The most significant core network and the canonical pathways were identified within the gene sets. All plots were generated using GraphPad Prism V.7 (GraphPad Software, La Jolla, California, USA).

RESULTS

Distinctive transcriptomic profiles in PMBC between patients who had a stroke and controls

PBMCs were isolated from the whole blood obtained from patients who had a stroke and controls (figure 1A). Ten patients who had an ischaemic stroke (four women, 68.8 ± 13.1 years old, and all Caucasian) were included. The median NIHSS score was 1.5 at admission (IQR 0–4). All other demographic characteristics of patients who had a stroke are described in table 1. The control group consists of the age-matched and sex-matched healthy subjects ($n=9$), four women; the mean age is 59.1 ± 16.8 years old and all are Caucasian.

After quality control, we analysed 93 713 genes from 12 156 cells of patients who had a stroke ($n=10$), and 89 325 genes from 14 146 cells of controls ($n=9$). Individual cell numbers analysed are shown in figure 2A. Most of the clusters contained cells from all participants, and replicates from the same patient demonstrated a tight correlation between two runs ($r=0.98$, online supplemental figure 1A,B). Using graph-based clustering of UMAP, we identified 11 cell clusters (figure 1B) in each subject based on the expression of canonical marker genes (figure 1C–E). Identified cell clusters and marker genes are CD14+ monocytes clusters (S100A9, LYZ and CD14), B cells (MS4A1 and CD79A), CD4+ T cells (CD3D and IL7R), CD8+ T cells (CD8A), CD16+ monocytes (FCGR3A and MS4A7), NK cells (GNLY and NKG7), megakaryocytes and megakaryocytes subtype cluster (PPBP and PF4), classical dendritic cells (CD1c and CLEC10A) and plasmacytoid dendritic cells (LILRA4, ITM2C, JCHAIN and




Figure 1 Study design and transcriptome profiling of PBMCs from controls and patients who had a stroke. (A) Schematic picture showing the overall study design; PBMCs were pulled from controls (n=9) and patients who had an acute ischaemic stroke (n=10), and single-cell RNA sequencing was performed. (B) Cell clusters were identified with UMAP projection of 101 481 cells from controls and patients who had a stroke. (C,E) Selected canonical cell markers were used to identify cell clusters. cDC, classical dendritic cell; MK, megakaryocyte; NK, natural killer; PBMC, peripheral blood mononuclear cell; pDC, plasmacytoid dendritic cell; UMAP, uniform manifold approximation and projection.

PTPRS). The CD14+ monocytes were distributed across two clusters, which we named CD14+ monocytes (a bigger cluster) and CD14+ monocytes subtype (a smaller cluster). Comparing the two clusters, CD14+ monocytes cluster expressed a strong unique signature of marker genes of CD14+ monocytes described previously, whereas in the CD14+ monocytes subtype cluster, the expression pattern of CD14+ monocyte marker genes was not as strong as in CD14+ monocytes cluster.

To investigate the changes of the cell cluster composition of patients who had a stroke, we analysed the relative percentage of cell clusters by individual subjects and

groups (figure 2A,B). CD14+ monocyte cluster was the biggest cluster in both groups (25.0% in controls and 24.0% in patients who had a stroke), and CD14+ monocyte subtype cluster was significantly reduced in patients who had a stroke as compared with controls (3.8% in patients who had a stroke and 9.4% in controls). The proportion of NK cell cluster also changed, showing a significant increase in patients who had a stroke (11.6%) compared with controls (6.2%, $p=0.022$). The relative percentage of other clusters are as follows: CD4+ T-cells cluster is 11.8% in controls and 14.3% in patients who had a stroke; CD8+ T-cells cluster is 12.7% in controls and

Table 1 Characteristics of patients who had a stroke

Subject characteristics	All patients (n=10)
Demographic characteristics	
Age (years), mean±SD	68.8±13.1
Sex, female, n (%)	4 (40)
Race	Caucasian (100%)
Hispanic	0
Risk factors, n (%)	
Hypertension	7 (70)
Diabetes	0
Hyperlipidaemia	2 (20)
Previous ischaemic stroke/transient ischaemic attack	0
Smoking (current and former within 5 years)	1 (10)
Alcohol (two or fewer drinks/day)	6 (60)
Medication, n (%)	
Antiplatelet	3 (30)
Anticoagulant	0
Lipid-lowering	4 (30)
Blood pressure medication	5 (50)
NIHSS, median (IQR 25–75)	1.5 (0–4)
Time intervals (min), median (IQR 25–75)	
Last known well to triage	111.5 (40.0–698.0)
Last known well to blood draw	297.5 (278.8–869.3)
Stroke location, n (%)	
Left cerebrum	3 (30)
Left cerebrum and cortical cerebrum	2 (20)
Left cerebrum and deep cerebrum	2 (20)
Right cerebrum	1 (10)
None	2 (20)
Vascular territory, n (%)	
Left ACA	2 (20)
Left MCA	6 (60)
Right ACA and right PCA	1 (10)
Acute treatment with intravenous tPA, n (%)	
Intravenous tPA	4 (40)
None	6 (60)
Days of hospital stay, median (IQR 25–75)	2.5 (1.0–4.3)

Last known well indicates the time before hospital arrival at which the patient was last known to be without the signs and symptoms of the current stroke.

ACA, anterior cerebral artery; MCA, middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale; PCA, posterior cerebral artery; tPA, tissue plasminogen activator.

12.7% in patients who had a stroke; CD16⁺ monocytes cluster is 10.3% in controls and 8.1% in patients who had a stroke; B-cells cluster is 13.6% in controls and 14.2% in patients who had a stroke; megakaryocytes cluster is 6.4% in controls and 4.8% in patients who had a stroke; megakaryocytes subtype cluster is 0.1% in controls and 3.0% in patients who had a stroke; classical dendritic cells cluster is 3.6% in controls and 2.8% in patients who had

a stroke; and plasmacytoid dendritic cells cluster is 1.0% in controls and 0.8% in patients who had a stroke (online supplemental table 1).

We also tested the cell composition using flow cytometry (figure 2C). Results obtained by measuring the conventional surface markers showed a similar pattern in the cell composition changes of patients who had a stroke; however, it was not the same. First, the NK cell population was significantly increased in patients who had a stroke (8.3% in controls and 15.0% in patients who had a stroke, $p=0.025$). Figure 2D is the representative figure showing the increased NK cell population in a patient who had a stroke. The monocyte population, especially the classical monocyte population (CD14⁺⁺/CD16[–]), was reduced in patients who had a stroke (22.7% in controls and 17.2% in patients who had a stroke). The relative composition of CD4⁺ T cells and CD8⁺ T cells were decreased in patients who had a stroke (33.1% in controls and 25.2% in patients who had a stroke of CD4⁺ T cells, and 8.8% in controls and 2.2% in patients who had a stroke of CD8⁺ T cells), which was not consistent with scRNA-seq results. Detailed results are shown in online supplemental table 2.

Increased numbers and enhanced activity of NK cells in ischaemic stroke

We further analysed the NK cell cluster by comparison of transcriptome expression patterns of patients who had a stroke with controls. First, we obtained the top 20 DEGs of NK cells (table 2 and figure 2E). Among the top 20 DEGs in the NK cell cluster, only two genes (CX3CR1 and GIMAP7) were upregulated in patients who had a stroke, while 18 DEGs were downregulated, such as CXCR4, DUSP2 and IL7R. The top five canonical pathways of all DEGs ($n=71$) of NK cells include NK cell signalling, PKR in interferon induction and p38 MAPK signalling, indicating an enhanced NK cell activity in stroke. The glucocorticoid receptor signalling is the strongest canonical pathway, although no direct patterns were found among DEGs (figure 2F). The leading network among DEGs of the NK cell cluster consisted of upregulated FAS ligand (FASL) and downregulated NFκB inhibitor alpha (NFκBIA), supporting our evidence that NK cell activity is enhanced (online supplemental figure 2). Pathway analysis with upregulated DEGs in the NK cell cluster of patients who had a stroke also demonstrated activated NK cell signalling. CX3CR1, DENND2D, PLEKHF1, CD300A, SH2D1A, GNAI3, FASLG, AOA, GIMAP6, GIMAP7, MYOM2 SYNE2, IL18RAP, ABI3, NCAM1, ADAM8 and PTGDR were involved in the pathway (figure 2G, orange bars).

Characterisation of CD14⁺ monocytes subclusters

We found two distinctive CD14⁺ monocyte clusters, and the proportion of the CD14⁺ monocyte subtype cluster was significantly reduced in patients who had a stroke. To characterise detailed changes of CD14⁺ monocyte transcriptomes in patients who had a stroke, we reanalysed 8701 cells of two CD14⁺ monocyte clusters; first,




Figure 2 Differences in NK cell population between controls and patients who had a stroke. (A) Top dot plot shows the total PBMC counts of each subject used in scRNA-seq. The bar plot shows the percentage of cell clusters in each subject. The average percentage of each cell cluster analysed using scRNA-seq (B) and flow cytometry (C) is shown in green for controls and orange for patients who had a stroke. From both scRNA-seq and flow cytometry, it is demonstrated that NK cell cluster is increased in patients who had a stroke. (D) Representative flow cytometry plot shows increased NK cell population in patients who had a stroke. (E) DEGs (adjusted $p < 0.05$) in NK cell clusters of patients who had a stroke compared with controls are demonstrated using a heatmap. (F) Ingenuity pathway analysis was performed with all DEGs in the NK cell cluster, demonstrating enhanced NK cell signalling. (G) Pathway analysis was performed with upregulated DEGs (orange) and downregulated DEGs (blue) of the NK cell cluster. Upregulated DEGs are involved in the activation of the NK cell-related pathway. cDC, classical dendritic cell; DEG, differentially expressed gene; MK, megakaryocyte; NK, natural killer; PBMC, peripheral blood mononuclear cell; pDC, plasmacytoid dendritic cell; scRNA-seq, single-cell RNA sequencing; PKR, Protein Kinase R; STAT3, Signal Transducer and Activator of Transcription 3; MAPK, Mitogen-Activated Protein Kinase.

we named the larger cluster CD14+ monocyte A and the smaller cluster CD14+ monocyte B. The total number of cells for cluster A and cluster B from scRNA-seq were 6631 and 2070 cells, respectively; specifically, the 6631 cells of cluster A were composed of 2952 cells of patients who had a stroke and 3679 cells of controls, and the 2070 cells

of the cluster B were composed of 536 cells of patients who had a stroke and 1534 cells from controls. Fourteen clusters were identified in the UMAP (figure 3A). The cluster A was classified into nine subclusters (0, 2–4 and 6–10). Among nine subclusters obtained, the largest cluster (0) expressing upregulated KLF10, NLRC5 and

Table 2 Differentially expressed genes in natural killer cell cluster

Gene name	Average log ₂ fold change	Adjusted P value
GIMAP7	0.444456	0.000791
CX3CR1	0.370523	1.54E-10
H3F3B	-0.25528	0.008194
EIF3H	-0.27161	0.000524
RPL7	-0.27724	0.008482
BTG1	-0.29421	1.80E-08
CD74	-0.32504	5.67E-05
HLA.DRB1	-0.3366	0.000357
CD69	-0.35405	0.004314
NFKBIA	-0.35952	0.006542
TSC22D3	-0.36775	1.30E-05
CD3D	-0.41581	0.000151
TNFAIP3	-0.42138	0.004851
DUSP1	-0.42501	3.43E-05
LTB	-0.53388	7.39E-10
ZFP36	-0.55201	2.21E-13
IL7R	-0.69229	1.54E-17
DUSP2	-0.76309	3.16E-20
CXCR4	-0.79897	3.37E-29

Log₂ fold change, positive values indicate that the gene is more highly expressed in the patient who had a stroke compared with controls; adjusted p values are calculated based on Bonferroni correction.

ISG15, was significantly reduced in patients who had a stroke. Other clusters including subclusters 2, 3, 7 and 8 shared the dendritic cell features; subcluster 2 expressed PGD, CRIP1, XIST and TMEM176B. Subclusters 3 and 7 showed the distinctive expression of major histocompatibility complex (MHC) molecules (eg, HLA. DPA1, DPB1, DQB1, DRA and DRB1) and the increased cell numbers in patients who had a stroke (online supplemental figure 3). Especially, subcluster 7 showed a marked expression of FCGR3A, the marker gene of CD16+ monocytes; thus, it is likely an intermediate monocyte (CD14++CD16+) cluster. Subcluster 8 expressed interferon-related genes, such as IFI44, IFI44L, IFI6, IFIT1/2, IFIT3 and IFITM3, and its proportion was not changed in patients who had a stroke. Subcluster 9 showed a gene expression signature related to the neurological disorder including BDNF signalling pathway and spinal cord injury (online supplemental figure 4). EGR1/2, PTGS2, FOS, FOSB, DUSP1, IER2, ZFP36 and BTG2 were highly expressed in this cluster. Subclusters 6 and 10 were classified due to the expression of erythrocyte progenitor cells (HBB and HBA1/2) and megakaryocyte-related genes (PPBP and PF4), respectively. Based on these signatures, we named subclusters 0, 2–4, 7 and 8 as a dendritic cell-related CD14+ monocyte cluster.

CD14+ monocyte cluster B was classified into five subclusters (1, 5 and 11–13). Subcluster 1 was significantly reduced in patients who had a stroke, whereas the population of other clusters, including 11–13, was increased. Subclusters 1, 11 and 12 shared a cytokine signature such as GZMA/B, PRF1, NKG7, IFITM1, KLRD1, GNLY, CDL5 and CD247. Particularly subcluster 1 showed a marked expression of CD8A. Subcluster 5 expresses plasma cell-related genes such as MS4A1 and HLA.DQA1. Subcluster 13 expressed a CD4+ T-cell signature, including CD3D and IL7R. Based on the overall signatures, we named clusters 1, 9 and 11–13 as a NK cell-related CD14+ monocyte cluster. The most enriched canonical pathway of both CD14+ monocytes was EIF2 signalling, which was significantly inhibited in patients who had a stroke.

DISCUSSION

After an acute ischaemic stroke incidence, immune system dynamics change very fast and influence clinical progress significantly. Gene expressions of peripheral immune cells are correlated with the disease status of the brain after stroke; thus, it has been suggested as potential biomarkers aiding diagnosis of mild ischaemic stroke. In this study, we provided the dynamics of both cell population and gene expression of PBMCs after mild ischaemic stroke for a comprehensive understanding of the peripheral immune response.

NK cells play a role as a first-line defence against infected or transformed cells and mediate inflammatory responses by releasing cytokine and chemokine.¹⁹ In ischaemic stroke, NK cells are infiltrated extensively to the affected brain lesion; however, it is unclear how circulating NK cells behave over time after stroke. Studies have reported inconsistent results in changes of peripheral NK cells population due to the multiple factors such as different patient severity and the time of blood draw,²⁰ however, there is a consensus that the cytokines secreted by circulating NK cells change significantly after ischaemic stroke.²⁰ In our study, the number of NK cell population was increased in patients who had a stroke, which was confirmed from both analyses using transcriptomics and cell surface markers. It might be caused by the fact that our study samples were collected in the acute stage after stroke incidence from patients who had a relatively mild stroke. Previous studies showed that in patients who had a mild to moderate stroke, the percentage of circulating NK cells was slightly increased at day 7.²¹ However, in patients who had a moderate to severe stroke, the percentage of circulating NK cells was not changed significantly¹¹ or decreased²² after stroke. Decreased NK cell population is involved in reducing the cytokine level in blood. Cytokine deficiency in blood of patients who had an ischaemic stroke is known to contribute to immunodepression causing poststroke infection.²³ It is a critical complication resulting in the unfavourable outcomes of ischaemic stroke, and previous reports have shown that NK cells are involved in this process.^{20–23} The recent preclinical




Figure 3 Changes of monocytes subclusters in patients who had a stroke. (A) Two CD14+ monocytes clusters were classified into 14 subclusters; CD14+ monocyte cluster A is classified into nine subclusters (0, 2–4 and 6–10), and CD14+ monocyte cluster B is classified into five subclusters (1, 9 and 11–13). (B) Based on the gene expression characteristics, cluster A is named dendritic cell-related CD14+ monocyte cluster (subclusters 0, 2–4, 7 and 8 in a circle in peach) and cluster B is named NK cell-related CD14+ monocyte cluster (subclusters 1, 9 and 11–13 in a circle in cyan). Besides, there is one plasma cell-related cluster (5), one erythrocyte progenitor cell-related cluster (6) and one megakaryocyte-related cluster (10). (C) The violin plot shows specifically expressed genes of each subcluster using classification. (D) The proportion of each subcluster was compared between controls and patients who had a stroke. (E) Individual variations of each subcluster in controls and patients who had a stroke are shown. Horizontal lines represent the average value for the proportion of each subcluster. *Significant differences ($p < 0.05$) between controls and patients who had a stroke. NK, natural killer; UMAP, uniform manifold approximation and projection.

study demonstrated that the risk of poststroke infection is increased when stroke severity is high.²⁴ Increased circulating NK cell population in the early stage of mild ischaemic stroke might prevent occurrence of poststroke infection by producing more cytokines. Indeed, in our study, the pattern of glucocorticoid receptor signalling, one of the main mechanisms of immunosuppression,²⁵ is not clearly defined in the pathway analysis of NK cells. A longitudinal study needs to be followed to understand the precise role of NK cells in mild ischaemic stroke and immunodepression.

In this study, the overall gene expression in NK cells in patients who had a stroke was changed significantly, showing a strong trend of increased cell activity. IFN- γ /p38 MAPK–Nuclear factor kappa B (NF κ B) pathway was the primary signalling cascade of activated NK cells. Generally, NF κ B activation induces a proinflammatory and proapoptotic response.²⁶ In ischaemic stroke, NF κ B signalling is involved in an acute response playing a role in blood–brain barrier disruption, inflammation and neuronal cell death.²⁷ NF κ B activity is also associated with stroke severity because the stroke size was reduced with inhibition of NF κ B in the animal model²⁸ and in patients who had a stroke.²⁹ Given its role in ischaemic stroke, the NF κ B pathway has been suggested as a therapeutic target of ischaemic stroke.³⁰ Our results suggest that the NF κ B pathway of NK cells would be a more specific target for mild ischaemic stroke treatment. Furthermore, we found that most DEGs in NK cells were downregulated in patients who had a stroke, although the overall activity is enhanced. It suggests that a post-transcriptional or post-translational modification might be involved in the underlying mechanism.³¹ miRNAs such as miR-451a or miR-122-5p were suggested to modulate NK cell activity after ischaemic stroke.³² Long-non-coding RNAs are other candidates to modulate NF κ B activity in the ischaemic condition.³³ Detailed signalling mechanism needs to be investigated further to develop the therapeutic target in NK cells of ischaemic stroke.

Historically, monocytes were classified into three subtypes: classical (CD14⁺⁺/CD16[–]), intermediate (CD14⁺⁺/CD16⁺) and non-classical monocytes (CD14⁺/CD16⁺⁺); however, transcriptomic studies have shown that monocyte subsets represent stages in a developmental sequence as classical monocytes differentiate into intermediate and non-classical monocytes.^{34–35} In the pathological condition, transcriptomic changes are more complex due to an active interaction with other immune cells.⁶ Thus, recently studies have tried to classify monocytes according to their transcriptomic characteristics using an scRNA-seq technology (e.g., MONO1-4).³⁶ In this study, we found three different monocyte clusters based on the transcriptomic analysis: dendritic cell-related CD14⁺ monocyte cluster, NK cell-related CD14⁺ monocyte and CD16⁺ monocyte cluster. The overall transcriptomic changes of monocytes in patients who had a stroke towards inactivity given the strongly inhibited EIF2 signalling. However, one of the subclusters has a profile

of DEGs that was relevant to the neurological disorder, because each cluster has different characteristics with a different timeline of activation. We suggest that DEGs of this cluster have potentials to be developed as prognostic or diagnostic biomarkers of ischaemic stroke or its therapeutics. In addition, we found CD14⁺ monocyte subclusters that were significantly reduced in patients who had a stroke. Because these clusters express cytokine-related genes including KLF10, NLRC5, ISG15 and CD8A, it might be explained that this phenomenon is caused by the direct or indirect interaction of monocytes and NK cells^{37–38} during an immune system disruption such as ischaemic stroke. These are the biggest subclusters in the CD14⁺ monocyte population; thus, further in-depth studies need to be performed to elucidate their roles in mild ischaemic stroke.

Our study has several limitations. First, subjects were recruited from one centre and all were Caucasian, which allows us to avoid an influence caused by race in the small-sized pilot study. In addition, we observed only one time point, although it is known that circulating immune cells dynamically change over time. However, we could observe the immediate immune response after the stroke event. Finally, although all patients of this study were diagnosed with a minor stroke, they are in various stages of ischaemic stroke and treatment. Findings might need to be interpreted carefully. Future studies enrolling a diverse subject population with longitudinal sample collections including homogenous clinical outcomes may help develop biomarkers to evaluate or predict patients' conditions.

Circulating immune cell dynamics are as critical as the ischaemic response in the brain after stroke because it can be developed as diagnostic biomarkers and therapeutic drugs. Our study provided a comprehensive view of peripheral immune response in mild ischaemic stroke. We suggest that NF κ B signalling in the NK cell population would be target therapeutic biomarkers of mild ischaemic stroke. Further, we suggest three different monocyte subgroups based on the transcriptome characteristics. Our transcriptome atlas of peripheral immune cells in patients who had a stroke will provide insights for future studies to discover blood biomarkers of ischaemic stroke, which assist diagnosis and guide treatment.

Author affiliations

¹College of Nursing, The University of Iowa, Iowa City, Iowa, USA

²National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland, USA

³Mo-Im Kim Nursing Research Institute, College of Nursing, Yonsei University, Seoul, South Korea

⁴National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA

⁵Predictiv Care, Inc, Sunnyvale, California, USA

⁶School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA

⁷College of Nursing, University of Tennessee Health Science Center, Memphis, Tennessee, USA

⁸Suburban Hospital, Bethesda, Maryland, USA

⁹National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

Acknowledgements We thank all patients and their families for participating in the research, and the NIH Stroke Team at Suburban Hospital for the care of the patients and collection of data.

Contributors Y-EC contributed to the acquisition and interpretation of the data, and drafted and revised the manuscript; HL contributed to the data acquisition and revised the manuscript; HB contributed to the revision of the manuscript; HK contributed to the the data acquisition, interpretation of data and revision of the manuscript; SY contributed to the analysis and interpretation of data and revision of the manuscript; RV contributed to the data acquisition; AC contributed to the the design of the project and revision of the manuscript; MJR contributed to the sample collection at the hospital; MA contributed to the management of the clinical study and revision of the manuscript; LL contributed to the the design of the project and revision of the manuscript; JG contributed to the design of the project and revision of manuscript.

Funding This research was supported by the Intramural Research Program of the National Institutes of Health/National Institute of Neurological Disorders and Stroke and National Institute of Nursing Research (NIH ZIANS003043 and NIH ZIANS000015).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by patients presenting to the emergency department at Suburban Hospital in Bethesda Maryland. Patients are a subset from an ongoing protocol, Natural History of Stroke Study in Suburban Hospital, approved by the National Institutes of Health (NIH) institutional review board (IRB) (NCT00009243). Blood samples from healthy donors to be used as controls were obtained through the NIH blood bank under an approved IRB protocol (NCT00001846). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Young-Eun Cho <http://orcid.org/0000-0003-3017-6990>

REFERENCES

- Writing Group Members, Mozaffarian D, Benjamin EJ, *et al.* Heart disease and stroke Statistics-2016 update: a report from the American heart association. *Circulation* 2016;133:e38–60.
- Murphy SL, Kochanek KD, Xu J, *et al.* Mortality in the United States, 2014. *NCHS Data Brief* 2015;1–8.
- Bustamante A, López-Cancio E, Pich S, *et al.* Blood biomarkers for the early diagnosis of stroke: the Stroke-Chip study. *Stroke* 2017;48:2419–25.
- Amarencu P, Lavallée PC, Monteiro Tavares L, *et al.* Five-Year risk of stroke after TIA or minor ischemic stroke. *N Engl J Med* 2018;378:2182–90.
- Shoamanesh A, Preis SR, Beiser AS, *et al.* Circulating biomarkers and incident ischemic stroke in the Framingham offspring study. *Neurology* 2016;87:1206–11.
- Park J, Chang JY, Kim JY, *et al.* Monocyte transmodulation: the next novel therapeutic approach in overcoming ischemic stroke? *Front Neurol* 2020;11:578003.
- ElAli A, Jean LeBlanc N. The role of monocytes in ischemic stroke pathobiology: new avenues to explore. *Front Aging Neurosci* 2016;8:29.
- Liu H, Liu K, Pei L, *et al.* Monocyte-to-High-Density lipoprotein ratio predicts the outcome of acute ischemic stroke. *J Atheroscler Thromb* 2020;27:959–68.
- Ye Z, Jin Y, Li H, *et al.* Association of Tim-4 expression in monocyte subtypes with clinical course and prognosis in acute ischemic stroke patients. *Int J Neurosci* 2020;130:906–16.
- De Raedt S, De Vos A, Van Binst A-M, *et al.* High natural killer cell number might identify stroke patients at risk of developing infections. *Neurol Neuroimmunol Neuroinflamm* 2015;2:e71.
- Peterfalvi A, Molnar T, Banati M, *et al.* Impaired function of innate T lymphocytes and NK cells in the acute phase of ischemic stroke. *Cerebrovasc Dis* 2009;28:490–8.
- Iadecola C, Buckwalter MS, Anrather J. Immune responses to stroke: mechanisms, modulation, and therapeutic potential. *J Clin Invest* 2020;130:2777–88.
- Jakubczik C, Gautier EL, Gibbings SL, *et al.* Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. *Immunity* 2013;39:599–610.
- Dobin A, Davis CA, Schlesinger F, *et al.* Star: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29:15–21.
- Butler A, Hoffman P, Smibert P, *et al.* Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* 2018;36:411–20.
- Stuart T, Butler A, Hoffman P, *et al.* Comprehensive integration of single-cell data. *Cell* 2019;177:1888–902.
- Chen EY, Tan CM, Kou Y, *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* 2013;14:128.
- Kuleshov MV, Jones MR, Rouillard AD, *et al.* Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res* 2016;44:W90–7.
- Li Y, Zhu Zi-Yu, Huang Ting-Ting, *et al.* The peripheral immune response after stroke—A double edge sword for blood-brain barrier integrity. *CNS Neurosci Ther* 2018;24:1115–28.
- Chen C, Ai Q-D, Chu S-F, *et al.* NK cells in cerebral ischemia. *Biomed Pharmacother* 2019;109:547–54.
- Yan J, Greer JM, Etherington K, *et al.* Immune activation in the peripheral blood of patients with acute ischemic stroke. *J Neuroimmunol* 2009;206:112–7.
- Jiang C, Kong W, Wang Y, *et al.* Changes in the cellular immune system and circulating inflammatory markers of stroke patients. *Oncotarget* 2017;8:3553–67.
- Wang Y, Zhang JH, Sheng J, *et al.* Immunoreactive cells after cerebral ischemia. *Front Immunol* 2019;10:2781.
- Shim R, Wen SW, Wanrooy BJ, *et al.* Stroke severity, and not cerebral infarct location, increases the risk of infection. *Transl Stroke Res* 2020;11:387–401.
- Shi K, Wood K, Shi F-D, *et al.* Stroke-Induced immunosuppression and poststroke infection. *Stroke Vasc Neurol* 2018;3:34–41.
- Shih R-H, Wang C-Y, Yang C-M. NF-kappaB signaling pathways in neurological inflammation: a mini review. *Front Mol Neurosci* 2015;8:77.
- Kraft P, Schleicher R, Olbrich M, *et al.* Platelet derived FasL contributes to apoptosis in stroke. *Thromb Haemost* 2016;116:998–1000.
- Ali A, Shah FA, Zeb A, *et al.* NF-κB Inhibitors Attenuate MCAO Induced Neurodegeneration and Oxidative Stress-A Reprofile Approach. *Front Mol Neurosci* 2020;13:33.
- Harari OA, Liao JK. NF-κB and innate immunity in ischemic stroke. *Ann N Y Acad Sci* 2010;1207:32–40.
- Howell JA, Bidwell GL. Targeting the NF-κB pathway for therapy of ischemic stroke. *Ther Deliv* 2020;11:113–23.
- Huang B, Yang X-D, Lamb A, *et al.* Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. *Cell Signal* 2010;22:1282–90.
- Kong Y, Li S, Cheng X, *et al.* Brain ischemia significantly alters microRNA expression in human peripheral blood natural killer cells. *Front Immunol* 2020;11:759.
- Xu Q, Deng F, Xing Z, *et al.* Long non-coding RNA C2dat1 regulates CaMKIIδ expression to promote neuronal survival through the NF-κB signaling pathway following cerebral ischemia. *Cell Death Dis* 2016;7:e2173.
- Yona S, Kim K-W, Wolf Y, *et al.* Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* 2013;38:79–91.
- Varol C, Landsman L, Fogg DK, *et al.* Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. *J Exp Med* 2007;204:171–80.
- Villani A-C, Satija R, Reynolds G, *et al.* Single-Cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. *Science* 2017;356:eaah4573.
- Clavijo-Salomon MA, Salcedo R, Roy S, *et al.* Human NK cells prime inflammatory DC precursors to induce Tc17 differentiation. *Blood Adv* 2020;4:3990–4006.
- Burel JG, Pomaznoy M, Lindestam Arlehamn CS, *et al.* Circulating T cell-monocyte complexes are markers of immune perturbations. *Elife* 2019;8:e46045.